- ICH GCP
- EU臨床試験登録
最新の試験
EudraCT Number: 2022-002954-25 | Sponsor Protocol Number: ASND0036 | Start Date: | |||||||||||
Sponsor Name: Ascendis Pharma Growth Disorders A/S | |||||||||||||
Full Title: ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in C... | |||||||||||||
Medical condition: Achondroplasia (ACH) in prepubertal children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005478-24 | Sponsor Protocol Number: DYNE251-DMD-201 | Start Date: | |||||||||||
Sponsor Name: Dyne Therapeutics, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participan... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IE (Ongoing) BE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002961-23 | Sponsor Protocol Number: ODO-TE-B301 | Start Date: | ||||||
Sponsor Name: Odonate Therapeutics, Inc. | ||||||||
Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally... | ||||||||
Medical condition: Patients with Breast Cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000640-14 | Sponsor Protocol Number: 1245.9 | Start Date: | |||||||||||
Sponsor Name: Boehringer ingelheim Pharma GmbH & Co KG | |||||||||||||
Full Title: A Phase IIb, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, ... | |||||||||||||
Medical condition: Type 2 Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002367-29 | Sponsor Protocol Number: ITM202203 | Start Date: | |||||||||||
Sponsor Name: Instituut van Tropische Geneeskunde Antwerpen | |||||||||||||
Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies... | |||||||||||||
Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000261-36 | Sponsor Protocol Number: HTA-HG5-02 | Start Date: | |||||||||||
Sponsor Name: HOLOSTEM TERAPIE AVANZATE S.R.L. | |||||||||||||
Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED ... | |||||||||||||
Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002896-17 | Sponsor Protocol Number: V1.17.05.2013 | Start Date: | ||||||
Sponsor Name: Orthopädisches Spital Speising | ||||||||
Full Title: Functional evaluation of two therapy concepts: dynamic orthoses and BoNT | ||||||||
Medical condition: Infantile cerebral palsy | ||||||||
|
||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: AT (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012667-34 | Sponsor Protocol Number: BRONCHIOLITIS | Start Date: | |||||||||||
Sponsor Name: Oslo University Hospital - Ullevål | |||||||||||||
Full Title: BRONCHIOLITIS, OPTIMAL TREATMENT IN INFANTS AND PROGNOSIS | |||||||||||||
Medical condition: Acute bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006816-31 | Sponsor Protocol Number: P060104 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Effet du mazindol sur le Trouble Déficit de l'Attention/Hyperactivité chez l'enfant : étude prospective pilote (phase II) d'efficacité, de tolérance et de pharmacocinétique | |||||||||||||
Medical condition: Enfants de 6 à 12 ans présentant un TDAH et suivi dans le Service de Psychopathologie de l'Enfant et de l'Adolescent de l'Hôpital Robert Debré | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004039-10 | Sponsor Protocol Number: NL78130.041.21 | Start Date: | |||||||||||
Sponsor Name: UMC Utrecht - Van Creveldkliniek | |||||||||||||
Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study | |||||||||||||
Medical condition: Congenital hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |